Shelly Seward - Concepedia

Author

Shelly Seward

Also Known As

, S SEWARD, S. M. Seward, S. Seward, S.M. Seward, Samantha Holmes Seward, Shelly M Seward, Shelly M. Seward, Shelly Marie Seward, Shelly Seward

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Wayne State University The Barbara Ann Karmanos Cancer Institute Henry Ford Health System The Ohio State University University of Oklahoma Health Sciences Center

About

Shelly Seward is an author at Wayne State University specializing in medicine, oncology, and ovarian cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	385
2	Obstetrics	7	7	214
3	Cell Biology	4	4	187
4	Health Sciences	1	1	16
5	Immunology	1	1	37

Shelly Seward

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors Raffit Hassan, George R. Blumenschein, Kathleen N. Moore, Journal of Clinical Oncology	2020	164
Phase 1 dose‐escalation study of mirvetuximab soravtansine (<scp>IMGN853</scp>), a folate receptor α‐targeting antibody‐drug conjugate, in patients with solid tumors Kathleen N. Moore, Hossein Borghaei, David M. O’Malley, Cancer	2017	133
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine Lainie P. Martin, Jason Konner, Kathleen N. Moore, Gynecologic Oncology	2017	125
Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells Sanjeev Kumar, Christopher S. Bryant, Sreedhar Chamala, Molecular Cancer	2009	92
Sulforaphane induces cell cycle arrest by protecting RB-E2F-1 complex in epithelial ovarian cancer cells Christopher S. Bryant, Sanjeev Kumar, Sreedhar Chamala, Molecular Cancer	2010	72
Expression of GLUT-1 in epithelial ovarian carcinoma: Correlation with tumor cell proliferation, angiogenesis, survival and ability to predict optimal cytoreduction Assaad Semaan, Adnan Munkarah, Haitham Arabi, Gynecologic Oncology Optimal CytoreductionOncogenic AgentMedicineEpithelial Ovarian CarcinomaGynecology	2010	66
MicroRNA-101 Inhibits Growth of Epithelial Ovarian Cancer by Relieving Chromatin-Mediated Transcriptional Repression of p21waf1/cip1 Assaad Semaan, Aamer Qazi, Shelly Seward, Pharmaceutical Research Transcriptional RegulationMicrorna-101 Inhibits GrowthEpithelial Ovarian CancerMedicineCancer Cell Biology	2011	63
Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis Kathleen N. Moore, James Java, K.N. Slaughter, Gynecologic Oncology Advanced Cervical CancerCervical CancerCancer DetectionMedicineCancer Management	2016	49
Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR). George R. Blumenschein, Raffit Hassan, Kathleen N. Moore, Journal of Clinical Oncology Surgical OncologySolid TumorsImmunologyPathologyImmunotherapeutics	2016	37
Prognostic Impact of Laterality in Malignant Ovarian Germ Cell Tumors Haider Mahdi, Sanjeev Kumar, Shelly Seward, International Journal of Gynecological Cancer	2011	32

Page 1